287 related articles for article (PubMed ID: 37075068)
21. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
22. The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics.
Fitzgerald KA; Guo J; Tierney EG; Curtin CM; Malhotra M; Darcy R; O'Brien FJ; O'Driscoll CM
Biomaterials; 2015 Oct; 66():53-66. PubMed ID: 26196533
[TBL] [Abstract][Full Text] [Related]
23. Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
Gómez Rivas J; Carrion DM; Alvarez-Maestro M; Cathelineau X; Sanchez-Salas R; Di Lorenzo G; Di Maio M; Paul A; Martinez-Piñeiro L; Sartor O; Saad F; Debruyne F
Minerva Urol Nefrol; 2019 Oct; 71(5):445-456. PubMed ID: 31353876
[TBL] [Abstract][Full Text] [Related]
24. New developments in the treatment of castration resistant prostate cancer.
Wadia R; Petrylak DP
Asian J Androl; 2014; 16(4):555-60. PubMed ID: 24759588
[TBL] [Abstract][Full Text] [Related]
25. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
[TBL] [Abstract][Full Text] [Related]
26. Molecular imaging with theranostic nanoparticles.
Jokerst JV; Gambhir SS
Acc Chem Res; 2011 Oct; 44(10):1050-60. PubMed ID: 21919457
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer.
Adjei IM; Sharma B; Peetla C; Labhasetwar V
J Control Release; 2016 Jun; 232():83-92. PubMed ID: 27090164
[TBL] [Abstract][Full Text] [Related]
28. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
Nishizawa K; Hattahara K; Onishi H; Yoshida T
Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
[TBL] [Abstract][Full Text] [Related]
29. Integrating transcriptomics and network analysis-based multiplexed drug repurposing to screen drug candidates for M2 macrophage-associated castration-resistant prostate cancer bone metastases.
Chang J; Jiang Z; Ma T; Li J; Chen J; Ye P; Feng L
Front Immunol; 2022; 13():989972. PubMed ID: 36389722
[TBL] [Abstract][Full Text] [Related]
30. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
31. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
32. Development and prevalence of castration-resistant prostate cancer subtypes.
Vellky JE; Ricke WA
Neoplasia; 2020 Nov; 22(11):566-575. PubMed ID: 32980775
[TBL] [Abstract][Full Text] [Related]
33. Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
Luna Velez MV; Paulino da Silva Filho O; Verhaegh GW; van Hooij O; El Boujnouni N; Brock R; Schalken JA
Prostate; 2022 May; 82(6):657-665. PubMed ID: 35098567
[TBL] [Abstract][Full Text] [Related]
34. MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer.
Sarveswaran S; Ghosh R; Morisetty S; Ghosh J
PLoS One; 2015; 10(4):e0122805. PubMed ID: 25875826
[TBL] [Abstract][Full Text] [Related]
35. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Ryan CJ; Saylor PJ; Everly JJ; Sartor O
Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
[TBL] [Abstract][Full Text] [Related]
36. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
37. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2016 Dec; 122(24):3848-3855. PubMed ID: 27505036
[TBL] [Abstract][Full Text] [Related]
38.
Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
[TBL] [Abstract][Full Text] [Related]
39. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
40. Delivery of enzalutamide
Gao Z; Huang J; Xie Z; Xin P; Huang H; Du T; Wu J; Huang H
Biomater Sci; 2022 Sep; 10(18):5187-5196. PubMed ID: 35833529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]